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Abstract
Background and Objective: Asthma is associated with airway narrowing in response to bronchoconstricting stimuli and
increased airway smooth muscle (ASM) mass. In addition, some studies have suggested impaired b-agonist induced ASM
relaxation in asthmatics, but the mechanism is not known.
Objective: To characterize the potential defect in b-agonist induced cAMP in ASM derived from asthmatic in comparison to
non-asthmatic subjects and to investigate its mechanism.
Methods: We examined b2-adrenergic (b2AR) receptor expression and basal b-agonist and forskolin (direct activator of
adenylyl cyclase) stimulated cAMP production in asthmatic cultured ASM (n=15) and non-asthmatic ASM (n=22). Based on
these results, PDE activity, PDE4D expression and cell proliferation were determined.
Results: In the presence of IBMX, a pan PDE inhibitor, asthmatic ASM had ,50% lower cAMP production in response to
isoproterenol, albuterol, formoterol, and forskolin compared to non-asthmatic ASM. However when PDE4 was specifically
inhibited, cAMP production by the agonists and forskolin was normalized in asthmatic ASM. We then measured the amount
and activity of PDE4, and found ,2-fold greater expression and activity in asthmatic ASM compared to non-asthmatic ASM.
Furthermore, inhibition of PDE4 reduced asthmatic ASM proliferation but not that of non-asthmatic ASM.
Conclusion: Decreased b-agonist induced cAMP in ASM from asthmatics results from enhanced degradation due to
increased PDE4D expression. Clinical manifestations of this dysregulation would be suboptimal b-agonist-mediated
bronchodilation and possibly reduced control over increasing ASM mass. These phenotypes appear to be ‘‘hard-wired’’ into
ASM from asthmatics, as they do not require an inflammatory environment in culture to be observed.
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Introduction
Clinically, asthma is characterized by variable degrees of
obstruction due to active airway smooth muscle (ASM) contrac-
tion, increased ASM mass, and increased airway mucus. Some
studies have also suggested that asthmatics have decreased b2AR
function compared to normal subjects [1,2], which is also
supported by animal and ex vivo studies [3,4,5,6,7]. While it is
now accepted that ASM cells play a central role in the
pathophysiology of asthma [8,9,10], the mechanisms of the
various phenotypes remain somewhat ill-defined. We and others
have previously reported that calcium (Ca
2+) homeostasis is altered
in asthmatic ASM cells [11,12]. The dysregulation of this second
messenger is associated with an increase in asthmatic ASM cell
proliferation that underlies the ASM remodelling which accom-
panies asthma [12,13], and accounts for the readily contracted
ASM in asthmatics upon exposure to agents such as methacholine.
Cyclic adenosine monophosphate (cAMP) is another important
regulatory second messenger, which mediates ASM cell relaxation
and inhibition of proliferation. cAMP production in ASM cells can
be caused by any of a number of expressed G-protein coupled
receptors (GPCRs) that couple to Gas which stimulates adenylyl
cyclase (AC). Therapeutically, b-agonists acting on b2AR
expressed on ASM are responsible for cAMP production and
the clinical effects. This pathway has been extensively dissected in
cells which have been recombinantly manipulated, and endoge-
nously expressing cells including human ASM. Nevertheless,
mechanisms of b2AR dysfunction in asthma have been hampered
by the potentially confounding effects of b-agonists and cortico-
steroids when using freshly obtained airway tissue. [2,14,15,16]. In
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and albuterol induced a reduction of membrane b2AR expression
by internalisation of the receptor [15,16]. Autoradiographic
enumeration of the b2AR has shown no decrease in asthmatic
tissue compare to non asthmatic [14], however bronchial tissue
from asthmatic patients are less responsive to b2-agonists in
comparison to non-asthmatics [2]. Additionally when primary
ASM cell lines are cultured the notion that mimicking the
inflammatory milieu is necessary has also potentially confounded
research in this area. b2AR is the most utilized target of asthma
therapeutics, both for rescue and prevention, with the use of both
short- and long-acting b-agonists. An additional response to b-
agonists is a reduction in human ASM cell proliferation [13], that
is also cAMP dependent. Thus, cAMP seems to be involved in
several pivotal events in ASM pathophysiology but its production
and regulation have not been directly investigated in ASM from
asthmatic patients.
Phosphodiesterases (PDE) act as key regulators of this pathway
by degrading cyclic nucleotides. PDEs represent a super family of
enzymes divided into 11 subfamilies that can degrade cytosolic
cAMP and cAMP. In human ASM cells, PDE4 has been found to
be the major PDE subtype that is involved in cAMP degradation
[17] and PDE4 inhibitors such as roflumilast and cilomilast have
been developed recently, in particular for the treatment of COPD.
We hypothesised that increased PDE4D in asthmatic airway
smooth muscle was contributing to the b2AR ‘‘defect’’ observed in
asthma. Using ASM cells from normal and asthmatic subjects b2-
agonist induced cAMPproduction was assessed. A profound decrease
in b-agonist stimulated cAMP was found, which led to additional
studies indicating a post-receptor phenomenon. Increased PDE
activity from increased PDE4D expression in asthmatic ASM was
found. Clinically studied PDE4 inhibitors eliminated the decrease in
b-agonist signalling to cAMP as well as cell proliferation.
Materials and Methods
Ethics Statement
The study was approved by the Ethics Review Committee of the
Sydney South West Area Health Service, Royal Prince Alfred
Hospital and The University of Sydney human research ethics
committee. All volunteers provided written informed consent.
We established primary cell cultures of human ASM cells from
explants of ASM bundles. These were obtained from macroscop-
ically normal surgical specimens following resection surgery for
thoracic lesions or lung transplantation, or from airway biopsies as
previously described [18]. Subject details are shown in Table S1.
Asthma was defined by GINA guidelines [19]. Human ASM cells
were maintained in DMEM medium supplemented with 10% FBS
in 5% CO2, 95% air incubator at 37uC. No other supplements
(such as antibiotics or pro-inflammatory agents) were utilized
during experimentation. ASM characterization was confirmed by
means of light microscopy and immunohistochemistry for smooth
muscle a-actin and calponin expression. Cells were studied at 80%
confluence between passages five and eight. From the time of
collection from the subjects to the first studies was typically at least
four weeks in culture.
cAMP production was assessed by stimulating 5610
3 ASM cells
for 5 minutes with log increasing concentrations of the b-agonists
isoproterenol from 10
29 Mt o1 0
25 M, albuterol (10
28 M and
10
27 M) and formoterol (10
28 M and 10
27 M). Measurements of
intracellular cAMP concentration were performed using the alpha
screen cAMP kit (Perkin Elmer, Melbourne, Australia) as
previously described [10]. In some experiments cAMP production
was also measured after stimulation with forskolin (10 mM) and
incubation with PDE inhibitors. The pan-PDE inhibitor 3-
Isobutyl-1-methylxanthine (IBMX) was used at 0.5 mM [20].
The PDE4 inhibitors roflumilast 1 mM (Nycomed) and cilomilast
Figure 1. Isoproterenol induced cAMP in ASM cells from asthmatic and non-asthmatic patients. cAMP degradation was inhibited by
addition of a pan-PDE inhibitor IBMX 0.5 mM (n=15 non asthmatic and n=10 asthmatic). Results are presented as mean 6 SEM. * denotes a
significant difference from non-asthmatic (P#0.05).
doi:10.1371/journal.pone.0020000.g001
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Aldrich, Castle Hill, NSW) were utilized at the indicated
concentrations based on reports showing complete and selective
inhibition of their respective isoenzymes [20,21,22,23,24].
The level of b2AR expression was assessed using flow cytometry
as previously described [10]. Briefly, fixed HASMC (80–90%
confluent), were blocked for 1 hour with 4% BSA in PBS,
incubated for 1 hour on ice with the primary antibody (rabbit anti-
human b2-adrenergic receptor, Abcam, San Francisco, USA),
washed twice in PBS and then incubated with the secondary
antibody (Alexa Fluor 488-conjugated goat anti-rabbit antibody;
Molecular Probes, Carlsbad, USA). An appropriate isotype control
was purchased from Becton Dickinson. Cells were then washed
again and resuspended in PBS prior to FACS analysis. Analysis
was conducted on Becton Dickinson FACSCalibur Sort using
CellQuest Software. Events were gated on forward and side scatter
parameters to include only live cells. Changes in fluorescence (i.e.,
receptor expression) were determined by measuring median
fluorescence of positive cells.
PDE3A, 4D and 5A expression in non-asthmatic and asthmatic
cells was assessed by western blotting using primary antibodies
directed against PDE3A, PDE4D and PDE5A. Briefly, whole
lysates from ASM cells were collected using 1% Triton X-100 lysis
buffer in the presence of 2 mM sodium orthovanadate, 1 mM
EDTA, 50 mg/ml aprotinin, 100 mM leupeptin, 1 mM 1,4-Dithio-
DL-Treitol, and 1 mM amino-ethyl-benzenesulfonyl fluoride
hydrochloride (all from Sigma-Aldrich). Cellular extracts were
reduced with b-mercaptoethanol, subjected to electrophoresis on a
10% acrylamide reducing gel, and transferred to PVDF
membrane (Immobilon TM-P; Millipore). The immunoblots were
then developed using rabbit anti–human PDE4D (Santa Cruz,
Santa Cruz, USA), rabbit anti–human PDE3A (Santa Cruz),
rabbit anti–human PDE5A (Santa Cruz) or mouse anti–human
GAPDH (Chemicon, Billerica, USA) overnight at 4uC. For
amplification, a biotinylated goat secondary anti–mouse IgG
(Bio-Rad Laboratories) or anti–rabbit IgG (Santa Cruz Biotech-
nology, Inc.) was added for 2 h at room temperature followed by a
streptavidin horseradish peroxidase complex (Dako Carpinteria,
USA). Immunoblots were revealed by enhanced chemilumines-
cence (Uptima, Montluc ¸on, France). Blot images were acquired
using BioCaptMW (Thermo Fisher Scientific, Pittsburgh, USA),
and band densities were quantified using Image J software.
PDE activity was assayed in human ASM cell lysates using a
colorimetric assay method from Biomol (Enzo life science,
Plymouth Meeting, USA), following the manufacturer’s protocol.
The measured levels of PDE activity were standardized to protein
content in the cell extracts to express the result as an optical
density value divided by protein concentration of the cell lysate.
For measurement of ASM cellular proliferation, 5610
4 ASM cells
per well wereseeded in a 6 wellplate and then quiesced with 1% BSA
in DMEM medium for 48 hours. Then, proliferation of the cells was
stimulated by replacing the medium with DMEMsupplemented with
10% FBS. The PDE inhibitors (IBMX 0.5 mM; roflumilast 1 mM
and cilomilast 1 mM) were also added at the time of stimulation. After
3 days, cells were harvested by trypsin and counted using a
hematocytometer, with at least 500 cells counted within the grid.
Figure 2. PDE activity is increased in asthmatic ASM cells. PDE activity was assayed in human ASM cell lysates using a colorimetric assay kit
(n=4 non-asthmatic and n=4 asthmatic). Cell lysates derived from non-asthmatic and asthmatic patients were used in the absence (Control) or
presence of PDE inhibitors (IBMX 0.5 mM and 5 mM; roflumilast 0.01 mM, 0.1 mM and 1 mM, milrinone 10 mM and cilomilast 1 mM). Data represent
mean 6 SEM of the OD activity value divided by protein concentration of the cell lysate. * Denotes a significant difference from control (P#0.05).
doi:10.1371/journal.pone.0020000.g002
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Dunnett’s post test. Post hoc tests were carried out when p,0.05
by ANOVA. Data were analysed using GraphPad Prism version
5.00 for Windows (GraphPad Software, San Diego, California,
USA). A probability level of 95% (P#0.05) was considered as the
threshold for statistical significance. Data are shown as mean6
SEM.
Results
Human ASM cells from asthmatic and non-asthmatic volun-
teers were stimulated with the b-agonist isoproterenol and cAMP
levels measured. Since the measurement of cAMP in these cells is
only possible in the presence of PDE inhibitors such as IBMX that
prevent cAMP degradation, in these initial cAMP experiments,
IBMX was used at the standard concentration of 0.5 mM (Fig. 1A).
These results revealed markedly lower cAMP levels in asthmatic
ASM, which were statistically different at 10
27 to 10
25 M, but a
trend was observed at all doses. A similar loss-of-function was
observed when the b-agonists albuterol and formoterol were
utilized (Fig S1).
We excluded the possibility that the difference was due to
differential b2AR expression on the ASM cell surface. Using flow
cytometry, we found no differences in b2AR expression between
asthmatic and non-asthmatic ASM cells (Fig S2A, B). Moreover,
there was no difference in the basal cAMP level in the absence of b-
agonist between the two cell groups (Fig S2C). We also assessed
cAMP production independent of the b2AR using stimulation of
ACwithforskolin. Asbefore,we found decreased cAMP production
in asthmatic compared with non-asthmatic ASM (Fig S2C).
Taken together, these results suggest that neither b2AR
expression, nor its coupling to AC can account for the decreased
b-agonist promoted cAMP stimulation. Rather, a post-AC defect
was suggested, particularly in the degradation of cAMP by PDE.
To confirm this hypothesis, we assessed PDE activity in
asthmatic and non-asthmatic ASM cells. Following isolation of
cellular proteins, we found that total PDE activity was higher (,2
fold) in asthmatic ASM cells compared to ASM cells derived from
non-asthmatic patients (Fig. 2). This is consistent with our findings
with regard to cAMP levels and PDE inhibition (Fig. 1). In the
non-asthmatic ASM cells IBMX at 0.5 mM reduced PDE activity
and this was not further reduced when the concentration was
increased to 5.0 mM, however in the asthmatic cells, further
reduction occurred (IBMX 0.5 mM=60% of effect of IBMX
5.0 mM, Fig. 2). To establish that PDE4 was the major PDE
responsible for degradation of cAMP, we independently utilized
IBMX or the specific PDE4 inhibitors roflumilast (1 mM, 0.1 mM
and 0.01 mM) and cilomilast (1 mM). Treatment of the asthmatic
cells with the specific PDE4 inhibitors resulted in a marked
increase in the amount of cAMP measured, suggesting that the
cAMP PDE-cAMP activity is predominantly dependent on PDE4
in ASM, and 0.5 mM IBMX is not sufficient to inhibit all PDE
activity from the asthmatic cells.
We then confirmed the involvement and specificity of PDE4 in
ASM cells by comparing the two specific PDE4 inhibitors with a
PDE3 inhibitor (milrinone) at standard concentrations known to
completely and selectively inhibite their respective isoenzyme [24].
We found no difference in b-agonist-induced cAMP production in
cells derived from asthmatic and non-asthmatic patients in the
presence of the two specific PDE4 inhibitors roflumilast and
cilomilast (Fig. 3A and 3B). As previously described [25] we also
confirmed that PDE3 was not involved in the degradation of
cAMP induced by b-agonists in ASM cells (Fig. 3C). This result
confirms the major role of PDE4 in ASM cells and suggests that
asthmatic cells specifically have greater PDE4 activities compared
to control cells.
Since PDE4D has previously been shown to be the specific
PDE4 subtype involved in the modulation of cAMP production in
ASM cells [25], we tested the hypothesis that the enhanced activity
is due to increased protein expression by measuring the amount of
PDE4D by western blots, and found significantly increased
expression in ASM cells from patients with asthma compared to
Figure 3. PDE4-specific inhibitors normalize asthmatic ASM
cAMP production. Isoproterenol (10
29 Mt o1 0
25 M) induced cAMP
in ASM cells from asthmatic and non-asthmatic patients. cAMP
degradation was inhibited by addition of different PDE inhibitors,
A: roflumilast 1 mM (n=7 non-asthmatic and n=5 asthmatic);
B: cilomilast 1 mM (n=5 non-asthmatic and n=5 asthmatic) and
C: milrinone 10 mM (n=3 non-asthmatic and n=3 asthmatic). Results
are presented as mean 6 SEM.
doi:10.1371/journal.pone.0020000.g003
Increased PDE4D in Asthma
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PDEs were also upregulated in the asthmatic cells we measured
the expression of PDE3A and PDE5A. As shown in Figures S3A
and S3B, we found no differences in the expression of those two
PDE subtypes between asthmatic and non-asthmatic ASM cells.
As asthmatic ASM cells are known to have a greater proliferation
rate than non-asthmatics, and b-agonists/cAMP inhibit ASM
proliferation [26], we also assessed if the altered PDE4 expression in
asthmatic ASM cells affected proliferation. As shown in Fig. 5,
asthmatic ASM cells proliferate at a greater rate than non-asthmatic
cells. When the PDE inhibitor IBMX or the two specific PDE4
inhibitors roflumilast and cilomilast were used, the proliferation of
the asthmatic cells was significantly decreased, however there was
no effect on the proliferation rate of the non-asthmatic cells (Fig. 5).
Discussion
The body of evidence for an intrinsic abnormality in ASM and
its signalling characteristics in asthma is increasing rapidly. This
study highlights, another particularly relevant difference between
the cellular properties of asthmatic and non-asthmatic ASM. Our
findings show that stimulation of the b2AR either by isoproterenol
or two clinically utilized b-agonists, albuterol and formoterol,
results in less cAMP production in asthmatic cells. b2AR
expression was not different between the two sets of cells and
forskolin-stimulated activities were also less in the asthmatic ASM
cells. These results pointed towards a post-receptor, post-AC
defect, and the use of isotype-specific PDE inhibitors revealed a
normalization of b-agonist stimulated cAMP levels. This result can
be explained by the increased activity of PDE in asthmatic ASM
cells. These results suggest that there is an increased activity of
PDE in asthmatic ASM cells, and, that this can be attributed to an
increase in the activity of PDE4. Moreover, we found that
asthmatic ASM cells overexpress the PDE4D isoform when
compared to non-asthmatic cells. As previously described by
Mehats et al, we found that PDE4 is the major PDE subtype
responsible for the degradation of cAMP in the ASM cell [25].
A potential defect in bAR signalling in asthmatics has been
suggested by a number of human and animal model studies. In
humans, these studies are particularly difficult since normal
subjects show a minimal to no FEV-1 response to b-agonists,
and in asthmatics the concurrent use of b-agonists or glucocor-
ticoids can alter b2AR expression and/or function. An early study
of extrapulmonary functions such as pupillary size suggested
autonomic dysregulation in asthmatics that was consistent with
b2AR dysfunction [1]. In ex vivo studies of asthmatic and non-
asthmatic airways, the potency of b-agonists has been reported to
be ,5–10-fold less in asthmatic airways [2], which was not
associated with a loss of b2AR expression [14]. In the ovalbumin-
sensitized animal model of inflammation and airway hyperre-
sponsiveness, b-agonist- promoted relaxation of methacholine
constricted airways is decreased compared to that in control mice
[3], which is also found in the IL-13 overexpression model [4].
Similar findings have been reported with animal or human
airways exposed to various pro-inflammatory cytokines, prosta-
noids or allergic serum [5,6,7]. These latter studies potentially
implicate locally generated factors from the inflammatory/
asthmatic milieu in bAR hyperresponsiveness, but do not directly
compare bAR function of ASM from non-asthmatic and asthmatic
airways. As indicated earlier, such studies must consider the effects
of treatment on b2AR expression and function. For example, in
normal subjects treated with 6 inhalations of the b-agonist
metaproterenol, in bronchoscopy-derived epithelial cells and
macrophages there was an approximate 70% decrease in b2AR
expression and 40–50% decrease in functional coupling to cAMP
[15]. Profound desensitization from 6–12 hours of submicromolar
concentrations of albuterol exposure [16] is also observed with
human bronchi using precision cut lung slices. Such desensitiza-
tion has been shown to be inhibited by glucocorticoids [16,27].
We have considered, though, that ASM from asthmatics may
have specific signalling characteristics due to genetic variation or
epigenetic mechanisms, such that when maintained in standard
culture media, differences between asthmatic and non-asthmatic
ASM signalling will be apparent. Under these circumstances there
would be no need for specialized media to mimic the asthmatic
milieu, and drug effects from treatment of the asthmatics would
not be an issue. As shown in the current study, b-agonist mediated
cAMP production is indeed abnormal in asthmatic ASM, being
substantially less than that in non-asthmatic ASM. Another
apparent phenotype in asthmatic ASM is increased Ca
2+
production from Gq-coupled receptor signalling, as we and others
have recently reported [11,12]. The consequences of these
aberrations, decreased b-agonist responsiveness and increased
responsiveness to bronchospastic stimuli, are entirely consistent
with the spectrum of clinical phenotypes observed in asthma. It is
important to note, though, that we do not suggest a secondary role
for inflammation in programming ASM pathobiology. Rather, we
propose that some phenotypes can be observed in asthmatic ASM
even in the absence of inflammation, pointing towards genetic or
epigenetic predisposition. Furthermore, they are likely modified
Figure 4. Enhanced PDE4D in asthmatic ASM. Western blot analysis of PDE4D. A: represents a typical western blot for PDE4D. The bands on the
left are from 3 non asthmatic, and on the right from 3 asthmatic patients. B: represents PDE4/GAPDH ratio mean 6 SEM (n=8 non-asthmatic and
n=8 asthmatic). * Denotes a significant difference from non-asthmatic (P#0.05).
doi:10.1371/journal.pone.0020000.g004
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by viral infection ref, crosstalk from other GPCRs, and
inflammatory events. In terms of the current work, a component
of this underlying predisposition for b2AR dysfunction may be
amenable to therapeutic intervention with PDE4 inhibitors.
Indeed, Rabe et al demonstrated the benefit of roflumilast in
COPD patients in a multicenter double blind randomized study of
24 weeks. They found an improvement in the postbronchodilator
FEV-1 and in health-related quality of life in patients treated with
this drug [28]. Moreover, another randomized, placebo-con-
trolled, double-blind study was conducted two years later over 12
months by Calverley et al. In this extended study, an improvement
of the postbronchodilator FEV-1 by roflumilast was also reported
[29]. In asthma, roflumilast treatment has been shown to reduce
airway hyperresponsiveness after histamine challenge in allergic
patients with mild asthma [30] and to improve FEV-1, asthma
symptom scores and rescue inhaler use in a 12 week randomized
double blind clinical study [31].
Finally in our study, we found that the increase in PDE4 activity
and expression may be involved in the hyperplasia of asthmatic
ASM cells. As we have previously described [12,18,32], asthmatic
ASM cells have a higher proliferation rate. In the present study, we
found that in asthmatic ASM cells, three days of complete and
selectivePDE4 inhibition could reduceproliferation toa rate similar
to that found in the non-asthmatic ASM cells. This finding is of
clinical relevance, as ASM cell remodelling is likely to be involved in
the decreased lung function associated with the disease, but remains
insensitive to the usual asthma therapies [33]. Our finding may
suggest,therefore,that PDE4 isa therapeutic targetofinterest inthe
area of ASM remodelling. The involvement of other PDEs in cell
proliferation elsewhere has been shown previously. For example, a
specific inhibitor of PDE7 decreased proliferation of murine natural
killer T cells [34], and the PDE inhibitor pentoxifylline decreased
proliferation of the rat epithelial cell line IEC18 [35].
In conclusion, this study demonstrates b2AR mediated cAMP
generation is impaired in asthmatic ASM caused by enhanced
cAMP degradation by PDE4, due to increased PDE4 expression.
This signalling bias appears to be ‘‘hard-wired’’ in asthmatic ASM
but can be mitigated by PDE4 inhibitors, suggesting additional
studies on therapeutics aimed at this nodal point.
Supporting Information
Figure S1 Isoproterenol (10
26 M and 10
25 M), albuterol
(10
28 M and 10
27 M) and formoterol (10
28 M and 10
27 M)
induced cAMP in ASM cells from asthmatic (n=3) and non-
asthmatic (n=3) patients. cAMP degradation was inhibited by
addition of 0.5 mM IBMX. Results are presented as mean 6
SEM. * denotes a significant difference from asthmatic (P#0.05).
(TIF)
Figure S2 ASM cell b2AR expression as assessed by flow
cytometry. A: Representative flow cytometry data for membrane
b2AR expression. ASM cells are stained with isotype control
(black) or b2AR antibody (red and blue). ASM cells were obtained
from non-asthmatic (red) and asthmatic (blue) patients. B: Data are
presented as the mean values 6 SEM for the median fluorescence
of positive cells. ASM cells were obtained from non-asthmatic
(white bar n=5) and asthmatic (black bar n=5) patients. NS=no
significant difference. C: cAMP production in ASM cells from
non-asthmatic (n=4) and asthmatic (n=5) patients. Cells are
either unstimulated or stimulated with forskolin (10 mM). Results
are presented as mean 6 SEM. * denotes a significant difference
from control (P#0.05). NS=no significant difference.
(TIF)
Figure S3 Western blot analysis of A: PDE3B (n=4 non-
asthmatic and n=4 asthmatic) and B: PDE5A (n=4 non-
asthmatic and n=4 asthmatic) expression in non-asthmatic and
asthmatic ASM cells. A typical western blot is shown for each PDE
and the data are summarized in the graph as PDE/GAPDH ratio
mean 6 SEM. The bands on the left are from non asthmatic, and
on the right from asthmatic patients. NS=no significant
difference.
(TIF)
Table S1 Demographics of patient data.
(DOCX)
Figure 5. Cell proliferation phenotypes differ between normal and asthmatic ASM. 5610
4 asthmatic (n=4) and non-asthmatic (n=4) ASM
cells per well were seeded and incubated with DMEM supplemented with FBS 10% only (black bars) or with 10% FBS in DMEM and the following PDE
inhibitors IBMX (0.5 mM), roflumilast (roflu, 1 mM) and cilomilast (cilo, 1 mM). ASM cells were counted after 3 days growth. Data represent mean 6
SEM of the number of cells after 3 days. * denotes a significant difference from FBS and { denotes a significant difference from non-asthmatic
(P#0.05).
doi:10.1371/journal.pone.0020000.g005
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PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e20000Acknowledgments
The authors thank Dr H.Tenor for the gift of roflumilast and advice on the
manuscript, and all the surgeons and pathologists of Sydney’s hospitals for
their help with the harvest of lung tissue.
Author Contributions
Conceived and designed the experiments: TT JKB KN LMM QG SBL
JLB BGO. Performed the experiments: TT. Analyzed the data: TT.
Contributed reagents/materials/analysis tools: PB. Wrote the paper: TT
JKB SBL JLB BGO.
References
1. Fraser CM, Venter JC, Kaliner M (1981) Autonomic abnormalities and
autoantibodies to beta-adrenergic receptors. N Engl J Med 305: 1165–1170.
2. Goldie RG, Spina D, Henry PJ, Lulich KM, Paterson JW (1986) In vitro
responsiveness of human asthmatic bronchus to carbachol, histamine, beta-
adrenoceptor agonists and theophylline. Br J Clin Pharmacol 22: 669–676.
3. Deshpande DA, Wang WCH, McIlmoyle EL, Robinett KS, Schillinger RM,
et al. (2010) Bitter taste receptors on airway smooth muscle bronchodilate by a
localized calcium flux and reverse obstruction. Nature Medicine, In Press.
4. McGraw DW, Elwing JM, Fogel KM, Wang WC, Glinka CB, et al. (2007)
Crosstalk between Gi and Gq/Gs pathways in airway smooth muscle regulates
bronchial contractility and relaxation. J Clin Invest 117: 1391–1398.
5. Laporte JD, Moore PE, Panettieri RA, Moeller W, Heyder J, et al. (1998)
Prostanoids mediate IL-1beta-induced beta-adrenergic hyporesponsiveness in
human airway smooth muscle cells. Am J Physiol 275: L491–501.
6. Moore PE, Lahiri T, Laporte JD, Church T, Panettieri RA, Jr., et al. (2001)
Selected contribution: synergism between TNF-alpha and IL-1 beta in airway
smooth muscle cells: implications for beta-adrenergic responsiveness. J Appl
Physiol 91: 1467–1474.
7. Hakonarson H, Herrick DJ, Serrano PG, Grunstein MM (1996) Mechanism of
cytokine-induced modulation of beta-adrenoceptor responsiveness in airway
smooth muscle. J Clin Invest 97: 2593–2600.
8. Dekkers BG, Maarsingh H, Meurs H, Gosens R (2009) Airway structural
components drive airway smooth muscle remodeling in asthma. Proc Am
Thorac Soc 6: 683–692.
9. Mahn K, Ojo OO, Chadwick G, Aaronson PI, Ward JP, et al. Ca2+
homeostasis and structural and functional remodelling of airway smooth muscle
in asthma. Thorax 65: 547–552.
10. Trian T, Moir LM, Ge Q, Burgess JK, Kuo C, et al. (2009) Rhinovirus-induced
Exacerbations of Asthma - How is the {beta}2-adrenoceptor Implicated?
Am J Respir Cell Mol Biol.
11. Mahn K, Hirst SJ, Ying S, Holt MR, Lavender P, et al. (2009) Diminished
sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) expression contributes to
airway remodelling in bronchial asthma. Proc Natl Acad Sci U S A 106:
10775–10780.
12. Trian T, Benard G, Begueret H, Rossignol R, Girodet PO, et al. (2007)
Bronchial smooth muscle remodeling involves calcium-dependent enhanced
mitochondrial biogenesis in asthma. J Exp Med 204: 3173–3181.
13. Stewart AG, Tomlinson PR, Wilson JW (1997) Beta 2-adrenoceptor agonist-
mediated inhibition of human airway smooth muscle cell proliferation:
importance of the duration of beta 2-adrenoceptor stimulation. Br J Pharmacol
121: 361–368.
14. Spina D, Rigby PJ, Paterson JW, Goldie RG (1989) Autoradiographic
localization of beta-adrenoceptors in asthmatic human lung. Am Rev Respir
Dis 140: 1410–1415.
15. Turki J, Green SA, Newman KB, Meyers MA, Liggett SB (1995) Human lung
cell beta 2-adrenergic receptors desensitize in response to in vivo administered
beta-agonist. Am J Physiol 269: L709–714.
16. Cooper PR, Panettieri RA, Jr. (2008) Steroids completely reverse albuterol-
induced beta(2)-adrenergic receptor tolerance in human small airways. J Allergy
Clin Immunol 122: 734–740.
17. Nino G, Hu A, Grunstein JS, Grunstein MM (2009) Mechanism regulating
proasthmatic effects of prolonged homologous beta2-adrenergic receptor
desensitization in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol
297: L746–757.
18. Roth M, Johnson PR, Borger P, Bihl MP, Rudiger JJ, et al. (2004) Dysfunctional
interaction of C/EBPalpha and the glucocorticoid receptor in asthmatic
bronchial smooth-muscle cells. N Engl J Med 351: 560–574.
19. From the Global Strategy for Asthma Management and Prevention, Global Initiative for
Asthma (GINA) 2010. Available from: http://www.ginasthma.org.
2 0 .G r o w c o t tE J ,S p i n kK G ,R e nX ,A f z a lS ,B a n n e rK H ,e ta l .( 2 0 0 6 )
Phosphodiesterase type 4 expression and anti-proliferative effects in human
pulmonary artery smooth muscle cells. Respir Res 7: 9.
21. Togo S, Liu X, Wang X, Sugiura H, Kamio K, et al. (2009) PDE4 inhibitors
roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated
fibroblasts. Am J Physiol Lung Cell Mol Physiol 296: L959–969.
22. Burgess JK, Oliver BG, Poniris MH, Ge Q, Boustany S, et al. (2006) A
phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in
vitro. J Allergy Clin Immunol 118: 649–657.
23. Cone J, Wang S, Tandon N, Fong M, Sun B, et al. (1999) Comparison of the
effects of cilostazol and milrinone on intracellular cAMP levels and cellular
function in platelets and cardiac cells. J Cardiovasc Pharmacol 34: 497–504.
24. Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, et al. The
preclinical pharmacology of roflumilast–a selective, oral phosphodiesterase 4
inhibitor in development for chronic obstructive pulmonary disease. Pulm
Pharmacol Ther 23: 235–256.
25. Mehats C, Jin SL, Wahlstrom J, Law E, Umetsu DT, et al. (2003) PDE4D plays
a critical role in the control of airway smooth muscle contraction. Faseb J 17:
1831–1841.
26. Tomlinson PR, Wilson JW, Stewart AG (1995) Salbutamol inhibits the
proliferation of human airway smooth muscle cells grown in culture: relationship
to elevated cAMP levels. Biochem Pharmacol 49: 1809–1819.
27. Brodde OE, Brinkmann M, Schemuth R, O’Hara N, Daul A (1985)
Terbutaline-induced desensitization of human lymphocyte beta 2-adrenocep-
tors. Accelerated restoration of beta-adrenoceptor responsiveness by prednisone
and ketotifen. J Clin Invest 76: 1096–1101.
28. Rabe KF, Bateman ED, O’Donnell D, Witte S, Bredenbroker D, et al. (2005)
Roflumilast–an oral anti-inflammatory treatment for chronic obstructive
pulmonary disease: a randomised controlled trial. Lancet 366: 563–571.
29. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D,
et al. (2007) Effect of 1-year treatment with roflumilast in severe chronic
obstructive pulmonary disease. Am J Respir Crit Care Med 176: 154–161.
30. Louw C, Williams Z, Venter L, Leichtl S, Schmid-Wirlitsch C, et al. (2007)
Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsive-
ness after allergen challenge. Respiration 74: 411–417.
31. Bateman ED, Izquierdo JL, Harnest U, Hofbauer P, Magyar P, et al. (2006)
Efficacy and safety of roflumilast in the treatment of asthma. Ann Allergy
Asthma Immunol 96: 679–686.
32. Johnson PR, Roth M, Tamm M, Hughes M, Ge Q, et al. (2001) Airway smooth
muscle cell proliferation is increased in asthma. Am J Respir Crit Care Med 164:
474–477.
33. Pepe C, Foley S, Shannon J, Lemiere C, Olivenstein R, et al. (2005) Differences
in airway remodeling between subjects with severe and moderate asthma.
J Allergy Clin Immunol 116: 544–549.
34. Goto M, Murakawa M, Kadoshima-Yamaoka K, Tanaka Y, Inoue H, et al.
(2009) Phosphodiesterase 7A inhibitor ASB16165 suppresses proliferation and
cytokine production of NKT cells. Cell Immunol 258: 147–151.
35. Diab-Assef M, Reimund JM, Ezenfis J, Duclos B, Kedinger M, et al. (2002) The
phosphodiesterase inhibitor, pentoxifylline, alters rat intestinal epithelial cell
proliferation via changes in the expression of transforming growth factors.
Scand J Gastroenterol 37: 206–214.
Increased PDE4D in Asthma
PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e20000